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Abstract: A new series of amino/nitro-substituted 3-arylcoumarins were synthesized and 
their antibacterial activity against clinical isolates of Staphylococcus aureus (Gram-positive) 
and Escherichia coli (Gram-negative) was evaluated. Some of these molecules exhibited 
antibacterial activity against S. aureus comparable to the standards used (oxolinic acid and 
ampicillin). The preliminary structure-activity relationship (SAR) study showed that the 
antibacterial activity against S. aureus depends on the position of the 3-arylcoumarin 
substitution pattern. With the aim of finding the structural features for the antibacterial 
activity and selectivity, in the present manuscript different positions of nitro, methyl, 
methoxy, amino and bromo substituents on the 3-arylcoumarin scaffold were reported. 
Keywords: amino/nitro substituted 3-arylcoumarins; Perkin reaction; antibacterial assays; 
S. aureus; E. coli 
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Drug discovery is considered a complex and slow activity. However, with the intention of 
discovering new chemical entities in a new and more efficient way, medicinal chemistry researchers 
have developed new approaches and methods. Some of the new products are based on diversity 
molecules found and extracted from natural sources. Coumarins are a large family of compounds of 
natural or synthetic origin, associated with remarkable pharmacological activities [1,2]. They occur 
naturally in plants and microorganisms and approximately 1,000 coumarin derivatives have been 
isolated from over 800 species [2]. The fused heterocyclic framework of coumarins has been used as a 
prototype scaffold for the synthesis of a wide variety of analogues in order to study and improve their 
biological properties. Its structural variety is responsible for the important place they occupy in the 
realm of natural products and synthetic organic chemistry [2,3]. Some coumarins have been studied for 
their antimicrobial [4–7], cardioprotective [8], anticancer [9,10], antioxidative [11] and enzymatic 
inhibition properties [12–17]. Goth described the antibacterial properties of coumarins for the first time 
in 1945 when he studied the dicoumarol (Figure 1) [18]. Some other coumarin derivatives have proven 
to display antibacterial and antifungal activities [19–22]. A study of coumarin derivatives substituted 
on the pyrone ring indicated that 3-carboxyl derivatives show significant activities [23]. Different  
4-substituted coumarins, such as 4-chlorocoumarins, exhibit also an interesting antimicrobial  
profile [24,25]. Novobiocin (Figure 1), chlorobiocin and coumermycin A1 are important natural 
occurring antibiotics in which the coumarin nucleus is present in their skeleton [26]. 
Figure 1. Chemical structures of dicoumarol and novobiocin. 
 
The most active of them is novobiocin, isolated from Streptomyces niveus and which is mainly 
active against Gram-positive bacteria. Although they antagonize the B subunit of the essential E. coli 
DNA gyrase supertwisting activity in vitro and the bacterial multiplication, they are not used in the 
clinic due to their relatively weak activity against Gram-negative bacteria, side effects and poor water 
solubility [4,26]. On the other hand, these three examples are antibiotics, which present activity  
against methicillin-resistant S. aureus (MRSA) [26]. The number of multidrug-resistant (MDR) 
bacteria is increasing and the Gram-positive MRSA are of particular importance. The ability of  
Molecules 2013, 18 1396 
 
 
S. aureus species to develop resistance to virtually all antibiotics is a major concern and the discovery 
of new antimicrobial agents is essential to combat this problem [27]. MRSA are often an important 
problem for severe infections in patients, especially if they are immunosuppressed, during long stays in 
hospitals [27]. The dramatic worldwide increase of dangerous infections by resistant and multi-resistant 
microbes makes, therefore, the search of new molecules and new chemical entities an important topic 
in medicinal chemistry [28,29]. As the ideal drug candidate has not been attained, an intensive search 
for new and innovative antimicrobials is still needed. Unfortunately, due to economic reasons, 
pharmaceutical companies have considerably decreased this effort in recent years [30]. 
2. Results and Discussion 
Based on previous findings in the area [24,25], and in our experience with substituted  
3-arylcoumarins [15,31,32], in the present work we proposed the synthesis and antibacterial evaluation 
of a series of different substituted amino/nitro 3-arylcoumarins (Scheme 1). With the aim of finding 
the structural features for the antibacterial activity and selectivity, we decided to explore the 
importance of the nature and position of small groups (methoxy, bromo, nitro, amino and methyl 
substituents) into both coumarin nucleus and 3-aryl ring (Scheme 1). 
Scheme 1. Synthesis of 3-arylcoumarins (1–11). 
 
Reagents and conditions: (a) NaH, acetic anhydride, r.t., 3 h; (b) H2, Pd/C, ethanol, r.t., 3 h. 
New derivatives 2, 4–7 and 9–11, as well as the already described compounds 1, 3 and 8 [33–36], 
were efficiently synthesized according to the synthetic protocol outlined in Scheme 1.  
3-Arylcoumarins 1–10 were synthesized in a dry Schlenk tube, in presence of sodium hydride and with 
acetic anhydride as solvent, at room temperature for three hours. The reaction mixture was purified by 
flash chromatography, using hexane/ethyl acetate as eluent in a proportion of 9:1. Starting from 
different commercially available substituted salicylaldehydes and the respectively substituted 
phenylacetic acids, we obtained ten derivates in good yields (60–75%). The derivative 11 was obtained 
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from 4, in ethanol, with palladium/carbon as catalyst and under hydrogen atmosphere for three hours. 
The reaction mixture was purified by flash chromatography, using hexane/ethyl acetate as eluent, in a 
proportion of 9:1. We obtained the desired derivate in good yield (80%). Then, two different 
methodologies were employed for the antibacterial evaluation of these compounds: disk diffusion test 
and microdilution method. Clinical antimicrobial drugs–oxolinic acid and ampicillin–were used as 
positive controls. The inhibition zones for growth inhibitory effects of the new compounds and 
controls were measured in millimetres (Table 1, method A). The minimum inhibitory concentrations 
(MICs) of the new compounds and controls were measured in microgram/millilitre (Table 1, method B). 
Table 1. In vitro antibacterial activity a of amino/nitro substituted 3-arylcoumarins 1–11 
(A) expressed as inhibition zones (mm) b and (B) expressed as MICs (µg/mL). 
Compounds 
Method A (mm) Method B (µg/mL) 
S. aureus E. coli S. aureus E. coli 
1 19 NA 128 - 
2 25 NA 64 - 
3 22 NA 32 - 
4 22 NA 32 - 
5 25 NA 64 - 
6 32 NA 8 - 
7 14 NA 256 - 
8 NA NA >512 - 
9 NA NA >512 - 
10 NA NA >512 - 
11 18 NA 128 - 
Oxolinic acid 26 31 2 <1 
Ampicillin 32 23 2 8 
a These results are average results of three experiments; b The compounds were used at the concentration of 
100 µg/disk and the inhibition zones are stated in mm; NA = not active; diameter of inhibition zone ≤ 5 mm. 
The obtained inhibition zones revealed that all the 6-nitro derivatives (compounds 1–7) presented 
antibacterial activity against S. aureus, showing inhibition zones ranging between 14 and 32 mm. The 
amino derivative 11 presented activity against the same bacterial strain. The 3-arylcoumarins nitro 
substituted only in the 3-aryl ring (compounds 8–10) were inactive against S. aureus in the in vitro 
disk diffusion test assays, independently of the relative position of this nitro group (para or meta 
positions). From the data, it is shown that compound 6 and ampicillin presented the same inhibition 
zone against S. aureus (32 mm) and a higher inhibition zone than the oxolinic acid (26 mm). Hence, 
the preliminary experimental data revealed that some of the tested compounds showed a very 
interesting activity profile against S. aureus when compared with the standards ampicillin and oxolinic 
acid. In addition, the different nature and position of the substituent in the coumarin scaffold seems to 
influence the antibacterial activity.  
In order to deeply study the antibacterial activities and quantify the previously mentioned 
information, MICs of compounds 1–11 against S. aureus were also determined. This second 
methodology (method B) is used to clarify and refine the previously results obtained by method A, 
which could be influenced by differences in the diffusion of the compounds. This study was performed 
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against the same bacteria strain, by a microdilution assay with serial dilutions (from 512 to 1 μg/mL) 
of the synthesized and the reference compounds. MICs of compounds 1–11 against E. coli were not 
evaluated, taking into account the lack of inhibition zones in the previous disk diffusion test  
(inhibition zones ≤ 5 mm). Analysing the MICs results for S. aureus, it is clear that the presence of a 
nitro substituent at the six position of coumarin moiety (compounds 1–7) is more beneficial than its 
presence only at meta or para positions of the 3-aryl ring (compounds 8–10).  
Compounds with nitro substituents either in the coumarin moiety and in the aryl group (compounds 
1 and 4) are not better than compounds where the nitro in the aryl ring is substituted for a methyl or a 
methoxy group (compounds 2 and 3 compared to compound 1, and compounds 5 and 6 compared to 
compound 4). However, compound 4 (MIC = 32 µg/mL), with the nitro substituent in meta position of 
the 3-aryl ring, is better than compound 1 (MIC = 128 µg/mL), with the same substituent in para 
position. The presence of a methyl group in the meta position is the best substitution when one nitro 
substituent is present at six position of the coumarin moiety (compound 6, MIC = 8 µg/mL). In 
general, meta substitutions are more favourable than para, being the meta-methyl substituent the most 
active, followed by meta-nitro and finally meta-methoxy. There is one exception to this conclusion. 
The introduction of a bromo atom at the same position was the worst substitution of the studied  
3-aryl-6-nitrocoumarins (compound 7, MIC = 256 µg/mL). A para-methyl substituent in the 3-aryl 
ring (compound 3, MIC = 32 µg/mL) is the best substitution in this para position. Therefore, the  
para-methyl substitution is better than the para-nitro and para-methoxy substitutions. Comparing the 
two positions in the 3-aryl ring, the substitutions by methyl groups are more favourable for the desired 
activity. The substitution of nitro by amino groups significantly decreases the activity of the described 
compounds (comparing compounds 4 and 11). 
In order to evaluate if there was a correlation between the activity and the lipophilicity, and to better 
understand the overall properties of the described compounds, logP (octanol/water partition 
coefficient) values were calculated using the Molinspiration property calculation program [37]. The 
results are presented in Table 2. 
Table 2. LogP (octanol/water partition coefficient) values calculated for the amino/nitro 













a The data was determined with Molinspiration calculation software [37]. 
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Analysing the obtained data, it can be concluded that there are no linear correlations between the 
lipophilicity and the activity of the compounds. Compounds 5 and 6 are two of the best compounds 
against S. aureus, presenting intermediate, but different, logP values (3.705 and 4.096 respectively). 
The compounds with the lowest (compound 11, 1.841) and the highest (compound 7, 4.457) logP 
presented activity. Compound 9, with the same logP as compound 5, resulted to be inactive. Also, 
compound 10, with the same lipophilicity profile as compound 3 (logP = 4.12), resulted to be inactive. 
Therefore, there are no clear correlation between activity and logP values. It is important to highlight 
that the calculated logP values for all the described compounds are lower than 5. 
3. Experimental 
3.1. Chemistry 
Merck supplied the entire chemicals used in the synthesis. Melting points (mp) are uncorrected 
were determined using a Reichert Kofler thermopan or in capillary tubes on a Büchi 510 apparatus and 
are uncorrected. 1H-NMR (300 MHz) and 13C-NMR (75.4 MHz) spectra were recorded with a Bruker 
AMX spectrometer. Chemical shifts (δ) are expressed in parts per million (ppm) using TMS as an 
internal standard. Spin multiplicities are given as s (singlet), d (doublet), dd (doublet of doublets) and 
m (multiplet). Mass spectrometry was carried out with a Kratos MS-50 or a Varian MAT-711 
spectrometer. Elemental analyses were performed by a Perkin-Elmer 240B microanalyzer and were 
within ±0.4% of calculated values in all cases. Flash Chromatography (FC) was performed on  
silica gel (Merck 60, 230–400 mesh); analytical TLC was performed on precoated silica gel plates 
(Merck 60 F254). 
General Procedure for the preparation of 3-arylcoumarins 1–10. In a 20 mL dry Schlenk tube, to a 
solution of the conveniently substituted salicylaldehyde (2.46 mmol) and the arylacetic acid (2.46 mmol), 
in acetic anhydride (6 mL), NaH (2.46 mmol) was added in small portions, and the reaction mixture 
was stirred for 3 hours, at room temperature. The obtained crude was filtered and washed with diethyl 
ether. The solid was then purified by flash chromatography (hexane/ethyl acetate 9:1) to give the 
desired coumarins 1–10.  
3-(4′-Methoxyphenyl)-6-nitrocoumarin (2). Pale yellow solid, 75% yield. Mp: 62–63 °C. 1H-NMR 
(CDCl3) δ (ppm): 3.80 (s, 3H, OCH3), 7.05 (d, 2H, H-3′, H-5′, J = 9.45 Hz), 7.62–7.69 (m, 3H, H-2′, H-6′, 
H-8), 8.36 (s, 1H, H-4), 8.73 (d, 2H, H-5, H-7, J = 2.93 Hz). 13C-NMR (CDCl3) δ (ppm): 55.9, 116.4, 
119.7, 127.9, 128.4, 128.6, 129.2, 132.2, 132.5, 134.3, 139.1, 139.4, 151.5, 155.8, 161.2. ESI-MS m/z: 
297 (M+, 100). Anal. Calcd. for C16H11NO5: C, 64.65; H, 3.73; Found: C, 64.67; H, 3.76. 
3-(3′-Nitrophenyl)-6-nitrocoumarin (4). Pale yellow solid, 69% yield. Mp: 87–88 °C. 1H-NMR (CDCl3) δ 
(ppm): 7.57–7.63 (m, 2H, H-8, H-6′), 7.71–7.77 (m, 1H, H-5′), 8.15 (s, 1H, H-4), 8.42-8.63 (m, 4H,  
H-4′, H-2, H-5, H-7). 13C-NMR (CDCl3) δ (ppm): 118.1, 120.2, 123.1, 123.3, 124.3. 124.5, 124.7, 
129.4, 133.6, 135.1, 141.2, 144.6, 147.9, 159.2, 160.5. ESI-MS m/z: 312 (M+, 100). Anal. Calcd. for 
C15H8N2O6: C, 50.70; H, 2.58. Found: C, 50.72; H, 2.60. 
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3-(3′-Methoxyphenyl)-6-nitrocoumarin (5). Pale yellow solid, 71% yield. Mp: 53–54 °C. 1H-NMR 
(CDCl3) δ (ppm): 3.71 (s, 3H, OCH3), 6.80 (s, 1H, H-2′), 7.17–7.22 (m, 3H, H-4′, H-5′, H-6′), 7.57 (d, 
1H, H-8, J = 6.5 Hz), 7.77 (s, 1H, H-5), 8.19 (d, 1H, H-7, J = 6.5 Hz), 8.39 (s, 1H, H-4). 13C-NMR 
(CDCl3) δ (ppm): 55.4, 84.5, 112.4, 115.5, 122.0, 123.5, 125.8, 126.8, 129.5, 129.7, 136.9, 145.7, 
153.2, 159.6, 168.7, 173.0. ESI-MS m/z: 297 (M+, 100). Anal. Calcd. for C16H11NO5: C, 64.65; H, 
3.73. Found: C, 64.63; H, 3.70. 
3-(3′-Methylphenyl)-6-nitrocoumarin (6). Pale yellow solid, 69% yield. Mp: 55–56 °C. 1H-NMR 
(CDCl3) δ (ppm): 2.25 (s, 3H, CH3), 6.90–7.30 (m, 5H, H-2′, H-4′, H-5′, H-6′, H-8), 7.75 (s, 1H, H-4), 
8.44 (d, 1H, H-7, J = 2.8 Hz), 8.62 (d, 1H, H-5, J = 2.8 Hz). 13C-NMR (CDCl3) δ (ppm): 21.5, 118.4, 
123.3, 124.5, 124.6, 124.8, 125.9, 126.6, 128.3, 128.5, 132.7, 138.4, 141.1, 144.6, 159.3, 160.9.  
ESI-MS m/z: 281 (M+, 100). Anal. Calcd. for C16H11NO4: C, 68.32; H, 3.94. Found: C, 68.31; H, 3.92. 
3-(3′-Bromophenyl)-6-nitrocoumarin (7). Pale yellow solid, 60% yield. Mp: 240–241 °C. 1H-NMR 
(CDCl3) δ (ppm): 7.12–7.26 (m, 2H, H-4′, H-5′), 7.46–7.71 (m, 5H, H-2′, H-6′, H-5, H-7, H-8), 7.78  
(s, 1H, H-4). 13C-NMR (CDCl3) δ (ppm): 117.9, 122.7, 123.1, 124.5, 124.6, 124.8, 127.9, 129.5, 129.7, 
130.8, 134.6, 140.7, 144.6, 159.1, 161.1. ESI-MS m/z: 345 (M+, 100). Anal. Calcd. for C15H8BrNO4: 
C, 52.05; H, 2.33. Found: C, 52.01; H, 2.30.  
6-Methoxy-3-(3′-nitrophenyl)coumarin (9). Pale yellow solid, 73% yield. Mp: 84–85 °C. 1H-NMR 
(CDCl3) δ (ppm): 3.77 (s, 3H, OCH3), 7.01–7.10 (m, 2H, H-5, H-7), 7.54–7.59 (m, 2H, H-5′, H-6′), 
7.71 (d, 1H, H-8, J = 7.6 Hz), 8.06–8.09 (m, 2H, H-2′, H-4′), 8.15 (s, 1H, H-4). 13C-NMR (CDCl3) δ 
(ppm): 56.7, 115.0, 116.8, 122.3, 124.9, 128.7, 130.2, 134.2, 135.5, 137.2, 138.0, 143.3, 148.3, 156.8, 
167.7, 172.7. ESI-MS m/z: 297 (M+, 100). Anal. Calcd. for C16H11NO5: C, 64.65; H, 3.73. Found: C, 
64.63; H, 3.70. 
6-Methyl-3-(4′-nitrophenyl)coumarin (10). Pale yellow solid, 75% yield. Mp: 100–101 °C. 1H-NMR 
(CDCl3) δ (ppm): 2.36 (s, 3H, CH3), 7.21 (d, 2H, H-7, H-8, J = 8.2 Hz), 7.38 (s, 1H, H-5), 7.63–7.70  
(m, 2H, H-2′, H-6′), 7.99–8.20 (m, 2H, H-3′, H-5′), 8.38 (s, 1H, H-4). 13C-NMR (CDCl3) δ (ppm): 
20.6, 122.6, 123.9, 125.1, 127.9, 130.2, 131.4, 136.4, 136.6, 136.8, 137.2, 148.1, 149.3, 170.2, 190.6. 
ESI-MS m/z: 281 (M+, 98). Anal. Calcd. for C16H11NO4: C, 68.32; H, 3.94. Found: C, 68.38; H, 3.99.  
Procedure for the Preparation of 3-(3′-Aminophenyl)-6-Aminocoumarin (11) 
The previously prepared 3-(3′-nitrophenyl)-6-nitrocoumarin (4, 2.46 mmol) was dissolved in 
ethanol (5 mL) and a catalytic amount of Pd/C was added to the mixture. The solution was stirred, at 
room temperature, under a H2 atmosphere, for 3 h. After completion of the reaction, the mixture was 
filtered to eliminate the catalyst. The obtained crude was then purified by flash chromatography 
(hexane/ethyl acetate 9:1) to give the desired coumarin 11 as a white solid in 80% yield. Mp:  
105–106 °C. 1H-NMR (CDCl3) δ (ppm): 4.02 (s, 2H, NH2), 6.50–6.55 (m, 1H, H-4′) 6.56 (s, 1H, H-2′),  
6.69–6.73 (m, 1H, H-6′) 6.80 (dd, 2H, H-5, H-7, J = 7.8, J = 2.4 Hz), 7.30–7.38 (m, 2H, H-5′, H-8), 
8.4 (s, 1H, H-4). 13C-NMR (CDCl3) δ (ppm): 114.9, 115.7, 116.7, 120.9, 123.6, 125.4, 127.2, 128.6, 
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133.7, 135.8, 136.2, 143.3, 145.5, 149.7, 161.9. ESI-MS m/z: 252 (M+, 100). Anal. Calcd. for 
C15H12N2O2: C, 71.42; H, 4.79. Found: C, 71.45; H, 4.82. 
3.2. Biological Assays 
Disk Diffusion Test: The antimicrobial activity of the compounds was assayed by the disk diffusion 
method, following the procedures of the Clinical and Laboratory Standards Institute (CLSI, 2006). The 
inoculum was prepared as a saline suspension of colonies from a 24 h Mueller Hinton Agar (MHA) 
(Cultimed, Barcelona, Spain) plate culture of the microorganisms, containing approximately 1 × 108 
colony forming units (CFU)/mL (OD620 of 0,09). Colony counts on inoculum suspension were verified 
by the plate dilution method using MHA plates and counting the bacterial colonies produced. The 
entire surface of the MHA plate was inoculated by streaking with the swab containing the inoculum. 
Antimicrobial solution (concentration of 10000 µg/mL) was prepared using DMSO as solvent. Sterile 
disks of 6 mm diameter (Liofilchem, Roseto degli Abruzzi, Italy) embedded in the drug at a final 
concentration of 100 µg/disk were kept on agar surface. Sterile disks embedded with DMSO were used 
as a negative control. The plates were incubated at 37 °C for 24 h. Zones of inhibition were measured 
in millimeter.  
Disk Minimum Inhibitory Concentrations (MICs): The MICs were evaluated using the broth 
microdilution method, following the procedures of the Clinical and Laboratory Standards Institute 
(CLSI, 2006). Broth microdilution tests were performed with 96 sterile flat-bottom microtiter plates 
(Becton Dickinson Labware Europe, Madrid, Spain). Antimicrobials were serially diluted (512 to  
1 μg/mL) in Mueller-Hinton Broth (MHB) (Cultimed) and then one hundred microliters of each 
dilution were deposited into each well. The inoculum was prepared by making a MHB suspension of 
colonies from a 24 h MHA (Cultimed) plate culture of the microorganisms, containing approximately  
1 × 108 colony forming units (CFU)/mL (OD620 of 0,09). The inoculum was diluted 1:100 in MHB to 
yield 1 × 106 CFU/mL. Ten microliters of this suspension was inoculated into the each well. Colony 
counts on inoculum suspension were verified by the plate dilution method using MHA plates and 
counting the bacterial colonies produced. MHB with and without inoculum was used as growth-control 
and negative control, respectively. The plates were incubated at 37 °C for 24 h. The MIC was 
established comparing the amount of growth in the wells containing the antimicrobial agents with the 
amount of growth in the growth-control wells both with the unaided eye and by using a photometric 
device (OD620). 
4. Conclusions  
In conclusion, in the present study it was shown that eight out of the eleven synthesized 
amino/nitro-substituted 3-arylcoumarins have inhibitory activity against S. aureus. MIC determinations 
proved that the tested compounds presented different profiles against S. aureus due to their 
substituents, being 3-(3′-methylphenyl)-6-nitrocoumarin (6) the best one. A nitro substituent at the  
6-position of the coumarin moiety seems to be essential for the antibacterial activity of this kind of 
compounds. The introduction of an amino substituent seems to decrease the described activity. The 
pharmacological potential of these amino/nitro-substituted 3-arylcoumarins confirms that this scaffold 
can be effectively optimized into a candidate for the treatment of some bacterial infectious diseases. 
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